Scholarly Index
Charles E. Geyer
Magee-Womens Hospital; 48,910 total citations; 281 total publications; best world rank #45
Magee-Womens Hospital
48,910Total citations
281Total publications
76H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Oncology | Lifetime | 452 | US 257 | 99.21 |
| Cancer Research | Lifetime | 287 | US 155 | 98.32 |
| Cancer Research | 2021-2025 | 50 | US 16 | 98.12 |
| Oncology | 2021-2025 | 254 | US 107 | 97.86 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 649 | US 227 | 92.16 |
| Cancer Treatment and Pharmacology | Lifetime | 169 | US 92 | 99.46 |
| Breast Cancer Treatment Studies | Lifetime | 166 | US 88 | 99.44 |
| HER2/EGFR in Cancer Research | Lifetime | 130 | US 68 | 99.38 |
| Advanced Breast Cancer Therapies | Lifetime | 147 | US 73 | 98.69 |
| Breast Lesions and Carcinomas | Lifetime | 692 | US 311 | 95.69 |
| PARP inhibition in cancer therapy | Lifetime | 881 | US 370 | 91.49 |
| Breast Cancer Treatment Studies | 2021-2025 | 45 | US 19 | 99.37 |
| HER2/EGFR in Cancer Research | 2021-2025 | 116 | US 41 | 98.22 |
| Cancer Treatment and Pharmacology | 2021-2025 | 139 | US 44 | 97.29 |
| Advanced Breast Cancer Therapies | 2021-2025 | 138 | US 49 | 97.71 |
| Estrogen and related hormone effects | 2021-2025 | 81 | US 35 | 93.76 |
| BRCA gene mutations in cancer | 2021-2025 | 261 | US 124 | 92.49 |
| Breast Lesions and Carcinomas | 2021-2025 | 241 | US 78 | 89.37 |
| PARP inhibition in cancer therapy | 2021-2025 | 556 | US 207 | 85.57 |